Prostate Cancer Therapeutics Market Size, Share, By Therapy Type (Hormone Therapy, Biologic Therapy, Chemotherapy, and Targeted Therapy), By Distribution Channel (Retail Pharmacies, Online Pharmacies and Hospitals Pharmacies), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2034

Prostate Cancer Therapeutics Market Size was valued at US$ 12.6 Billion in 2024 and is projected to grow at a CAGR of 8.9%to reach US$ 27.5 Billion by 2034.

Prostate cancer Therapeutics market help cancer patients in many ways, such as enhancing their quality of life and enabling them to do daily duties. Longer survival rates and a decreased rate of progression after a prostate cancer diagnosis have also been linked to physical activity. A recent study shows that even in cases of advanced prostate cancer, short bursts of high-intensity exercise can significantly increase tumour-suppressive responses.
The current situation of metastatic prostate cancer is linked to significant annual healthcare costs, which have gone up over time due to the approval of new oral medicines for the disease. Following the widespread adoption of PSA testing for prostate cancer screening, the incidence of metastatic prostate cancer at the population level in the USA dropped.

Key Drivers of Target Market:

Increasing Incidence Rates:

• Prostate cancer is one of the most prevalent cancers among men globally, with rising incidence rates due to aging populations and lifestyle factors. Due to many unhealthy lifestyles and diet the immunity has become weak over the years hence the number of prostate cancer patients are increasing rapidly

Advancements in Research and Development:

• Continuous research efforts are leading to the discovery of novel therapeutic targets and more effective treatment options, driving market growth.

Technological Innovations:

• Innovations in diagnostic tools (like imaging technologies) and therapeutic techniques (such as robotic-assisted surgeries and targeted therapies) are enhancing treatment outcomes.

Growing Awareness:

• Greater awareness about early detection and treatment options among patients and healthcare providers is contributing to higher diagnosis rates and early intervention.

Supportive Regulatory Environment:

• Favorable regulatory policies and expedited approval processes for new drugs and therapies are accelerating market entry and commercialization.

Restrains:

High Cost of Treatment:

• The cost of prostate cancer therapies, especially newer biologics and targeted therapies, can be prohibitively expensive, limiting access in certain regions or socioeconomic groups.

Side Effects of Therapies:

• Many treatments for prostate cancer, such as chemotherapy and hormone therapy, can have significant side effects that may affect patient compliance and quality of life.

The market is segmented based on Therapy Type, Distribution Channel, and Region.

Therapy Type Insight:

• Hormone Therapy: Hormone therapy, also known as androgen deprivation therapy (ADT), is a cornerstone of treatment for prostate cancer. It works by reducing levels of male hormones, particularly testosterone, which prostate cancer cells require to grow. This therapy can slow cancer progression and alleviate symptoms in advanced cases where the cancer has spread beyond the prostate gland.
• Biologic Therapy: Biologic therapies for prostate cancer involve using drugs that target specific molecules or pathways involved in cancer growth. These drugs are often derived from living organisms or their components and can include monoclonal antibodies, vaccines, or cytokines. Biologic therapies aim to enhance the body's immune response against cancer cells or block signals that promote tumor growth.
• Chemotherapy: Chemotherapy remains a critical treatment option for prostate cancer, especially when the disease has spread to other parts of the body (metastatic prostate cancer). Chemotherapy drugs work by targeting and killing rapidly dividing cells, including cancer cells.
• Targeted Therapy: Targeted therapies for prostate cancer focus on specific molecules or pathways that play key roles in cancer cell growth and survival. Unlike chemotherapy, which affects all rapidly dividing cells, targeted therapies aim to minimize damage to healthy cells while attacking cancer cells more precisely. Targeted therapies are often used in combination with other treatments, such as hormone therapy or chemotherapy, to improve outcomes and manage advanced prostate cancer more effectively.

Distribution Channel Insights

• Retail Pharmacies: In the context of prostate cancer therapeutics, retail pharmacies play a crucial role in providing convenience and accessibility to patients for medications such as hormone therapies, supportive care drugs, and over-the-counter supplements.
• Online Pharmacies: Online pharmacies operate through websites or mobile apps, allowing patients to purchase medications and healthcare products remotely and have them delivered to their doorstep. In the target market, online pharmacies offer convenience, especially for patients who may have mobility issues or live in remote areas.
• Hospital Pharmacies: Hospital pharmacies are integral to the management of prostate cancer therapeutics within healthcare institutions. They are responsible for preparing and dispensing medications prescribed by healthcare providers for inpatients and outpatients undergoing treatment. Hospital pharmacies stock a comprehensive range of oncology drugs, including chemotherapy agents, targeted therapies, and supportive medications used in the treatment of prostate cancer.

Regional Insights

• North America: In North America, particularly the United States and Canada, the prostate cancer therapeutics market is robust and driven by advanced healthcare infrastructure, high healthcare expenditure, and a strong focus on early detection and treatment. These countries have well-established pharmaceutical industries and academic research institutions that continuously innovate in cancer therapies. Government initiatives and healthcare policies support access to cutting-edge treatments, including hormone therapies, biologics, and targeted therapies.
• Europe: Europe represents a diverse market for prostate cancer therapeutics, with countries like Germany, the UK, France, and Italy leading in healthcare advancements. The region benefits from universal healthcare systems that prioritize access to oncology treatments, including chemotherapy and targeted therapies.
• Asia Pacific: Asia Pacific is witnessing rapid growth in the prostate cancer therapeutics market, driven by increasing incidence rates, improving healthcare infrastructure, and rising healthcare expenditure in countries like China, Japan, India, and South Korea. The region presents significant opportunities for market expansion due to its large population base and aging demographics.
• Latin America: Latin America's prostate cancer therapeutics market is characterized by varying levels of healthcare infrastructure and access across countries like Brazil, Mexico, Argentina, and Colombia.
• Middle East and Africa: The Middle East region, including countries like Saudi Arabia, UAE, and Qatar, is witnessing a growing demand for prostate cancer therapeutics due to rising cancer incidence rates and improving healthcare infrastructure. Governments in the region are investing in expanding oncology centers, introducing advanced medical technologies, and enhancing oncology treatment capabilities.

Prostate Cancer Therapeutics Market Report Scope:

Attribute	Details
Market Size 2024	USD 12.6 Billion
Projected Market Size 2034	USD 27.5 Billion
CAGR Growth Rate	8.9%
Base year for estimation	2023
Forecast period	2024 – 2034
Market representation	Revenue in USD Billion & CAGR from 2024 to 2034
Market Segmentation	By Therapy Type- Hormone Therapy, Biologic Therapy, Chemotherapy and Targeted Therapy By Distribution Channel- Retail Pharmacies, Online Pharmacies and Hospitals Pharmacies
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study segmented the target market report based on Therapy Type, Distribution Channel, and Region:

Segmentation:

By Therapy Type:

• Hormone Therapy
• Biological Therapy
• Chemo Therapy
• Targeted Therapy
• Others

By Distribution Channel:

• Retail Pharmacies
• Online Pharmacies
• Hospital Pharmacies

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating the Prostate Cancer Therapeutics Market include Bayer AG, Johnson & Johnson, AstraZeneca Plc., AstellaInc., Sanofi SA, Pfizer Inc., Dendreon, Sanpower Group Co. Ltd., Ipsen Group, TolmarInc, Endo Pharmaceuticals and AbbVie Inc.

• In March 2022, Novartis announced Pluvicto that has been approved by the US Food and Drug Administration (FDA) for the treatment of adult patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer that has spread to other parts of the body. It was a game changer for drug and prostate cancer therapeutics market.
• In March 2022, for the treatment of adults with advanced prostate cancer, BioPharma announced the launch of camcevi (leuprolide), a 42mg injection emulsion. The company further offers AccordConnects mobile application access for the management of Camcevi inventory manageme.
• In February 2023, Fusion Pharmaceuticals Inc. acquired an investigational new drug application from RadioMedix, Inc. The drug is in a Phase 2 clinical trial (the "TATCIST" trial) evaluating 225aAc-PSMA I&T, a small molecule targeting prostate-specific membrane antigen ("PSMA") expressed in prostate cancers. The alpha-emitting radiopharmaceutical being evaluated in the TATCIST trial is named FPI-2265.it has brought significant advancements.

• Bayer AG*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Johnson & Johnson
• AstraZeneca Plc.
• AstellaInc.
• Sanofi SA
• Pfizer Inc.
• Dendreon Corporation
• Sanpower Group Co. Ltd.
• Ipsen Group
• TolmarInc
• Endo Pharmaceuticals
• AbbVie Inc.

“*” marked represents similar segmentation in other categories in the respective section

Research Objective and Assumption

• Research Objectives
• Assumptions
• Abbreviations

Market Preview

• Report Description
• Market Definition and Scope
• Executive Summary

• Market Snippet, By Therapy Type
• Market Snippet, By Distribution Channel
• Market Snippet, By Country
• Opportunity Map Analysis

Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Market Trends
• Product Launch
• Merger and Acquisitions
• Impact Analysis
• PEST Analysis
• Porter’s Analysis

Market Segmentation, Therapy Type, Forecast Period Forecast Period up to 10 Years, (US$ Bn)

• Overview

• Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
• Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
• Segment Trends

• Hormone Therapy

• Overview
• Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

• Biological Therapy

• Overview
• Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Segment Trends

• Chemo Therapy

• Overview
• Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Segment Trends

• Targeted Therapy

• Overview
• Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Segment Trends

• Others

• Overview
• Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Segment Trends

Market Segmentation, Distribution Channels, Forecast Period Forecast Period up to 10 Years, (US$ Bn)

• Overview

• Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
• Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
• Segment Trends
• Hospital Pharmacy
• Overview
• Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

• Retail Pharmacy

• Overview
• Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

• Online Channels

• Overview
• Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Global Market, By Region, Forecast Period Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Regional Trends
• North America
  • Market Size and Forecast (US$ Bn), By Therapy Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Distribution Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • U.S.
    • Canada
• Europe
  • Market Size and Forecast (US$ Bn), By Therapy Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Distribution Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • UK
    • France
    • Germany
    • Russia
    • Italy
    • Rest of Europe
• Asia Pacific
  • Market Size and Forecast (US$ Bn), By Therapy Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Distribution Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years

• India

• Japan
• South Korea
• China
• Rest of Asia Pacific

• Latin America
  • Market Size and Forecast (US$ Bn), By Therapy Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Distribution Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • Brazil
    • Mexico
    • Rest of Latin America

• Middle East & Africa
  • Market Size and Forecast (US$ Bn), By Therapy Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Distribution Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • GCC
    • Israel
    • South Africa
    • Rest of Middle East

Company Profiles

• Bayer AG
• Johnson & Johnson
• AstraZeneca Plc.
• AstellaInc.
• Sanofi SA
• Pfizer Inc.
• Dendreon Corporation
• Sanpower Group Co. Ltd.
• Ipsen Group

The Last Word

• Future Impact
• About Us
• Contact